Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Renal tubule" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Renal tubule. noun. : the part of a nephron that leads away from a glomerulus, that is made up of a proximal convoluted tubule, loop of Henle, and distal convoluted tubule, and that empties into a collecting duct.
Method for the early detection of renal injury
A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1
Detection of NGAL in chronic renal disease
Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and / or maintaining a proper treatment regimen to slow or stop the progression of CRF.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Reagent sets and gene signatures for renal tubule injury
The invention discloses reagent sets and gene signatures for predicting onset of renal tubule injury in a subject. The invention also provides a necessary set of 186 genes useful for generating signatures of varying size and performance capable of predicting onset of renal tubule injury. The invention also provides methods, apparatuses and reagents useful for predicting future renal tubule injury based on expression levels of genes in the signatures. In one particular embodiment the invention provides a method for predict whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Method for the early identification and prediction of kidney injury
InactiveUS20090239242A1Convenient treatmentTransferasesDisease diagnosisCreatinine riseElevated blood
A method for the early identification and prediction of elevated blood creatinine levels resulting from a reduction in kidney function in a subject, comprises contacting a urine sample from the subject with a capture molecule for a biomarker specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of elevated blood creatinine levels resulting from a reduction in kidney function. The method can be used to detect Acute Kidney Injury (AKI) caused by many conditions or diseases or through the administration of drugs. The method can indicate and / or predict a reduction in kidney function significantly earlier than the current standard creatinine test. Methods for predicting a need for renal replacement therapy (RRT) are also disclosed.
Owner:ARGUTUS INTPROP
Method of modulating inflammatory response
InactiveUS7442546B2Improve the level ofLower Level RequirementsAntibacterial agentsBiocideImmunomodulationsRenal Tubule Epithelium
A method of immunomodulation by contacting the bodily fluid of a patient with renal tubule cells outside of the kidney.
Owner:RGT UNIV OF MICHIGAN
Method for the early detection of renal injury
InactiveUS20090142774A1Bioreactor/fermenter combinationsBiological substance pretreatmentsDiseaseSide effect
A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Method and kit for detecting the early onset of renal tubular cell injury
InactiveUS20090181407A1Organic active ingredientsMicrobiological testing/measurementSide effectNGAL Protein
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Method and kit for detecting the early onset of renal tubular cell injury
InactiveUS20090123941A1Bioreactor/fermenter combinationsOrganic active ingredientsSide effectNGAL Protein
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1
Methods for functional kidney imaging using small dendrimer contrast agents
Small dendrimer-based MRI contrast agents are disclosed to accumulate in renal tubules. The accumulation enables visualization of renal structure and function, permitting assessment of structural and functional damage to the kidneys. In a disclosed embodiment, six, small dendrimer-based MRI contrast agents were synthesized, and their pharmacokinetics, whole body retention, and renal MRI images were evaluated in mice. Surprisingly, despite having unequal renal clearance properties, all of the dendrimer agents clearly visualized the renal anatomy and proximal straight tubules of the mice better than Gd-[DTPA]-dimeglumine. Dendrimer conjugate contrast agents prepared from PAMAM-G2D, DAB-G3D, and DAB-G2D dendrimers were excreted rapidly and may be acceptable for use in clinical applications.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Bioartificial Renal Tubule
InactiveUS20090209019A1Faithfully reproducedValid choiceCell culture supports/coatingCell culture active agentsZona glomerulosaRenal Tubular Epithelial Cells
Owner:TOKAI UNIV
Chinese medicine composition for treating early and medium-term chronic renal failure
InactiveCN101194984ASignificant effectLower medical costsPowder deliveryUrinary disorderMetaboliteTurbidity
The invention belongs to the traditional medicine technical field, which relates to a traditional Chinese medicine composition for curing early and intermediate chronic renal failure. Under the guidance of a traditional Chinese medicine theory that 'interior accumulation is blood stasis' and 'chronic diseases transforming to collaterals is blood stasis', with the treatment principle of differentiation of symptoms and sighs, differentiation of channels, and based on the principle of strengthening body resistance and reducing turbidity, promoting blood circulation and removing blood stasis, the invention adopts traditional medicine such as lanceolata, epicedium, salvia miltiorrhizae, prepared rhubarb, perilla, peach kernel and the like, which are made into the compositions. Confirmed by clinical and animal experiments, the invention has the renal protecting functions of improving clinical symptoms of patients with early and intermediate chronic renal failure, reducing retention of metabolites of bodies, improving anemia, adjusting lipid and calcium-phosphorus metabolism, reducing the expression of fibrosis factors in nephridial tissues, preventing and treating glomerulosclerosis, lightening renal tubule damage and renal interstitial inflammatory cell infiltration and delaying renal fibrosis. The invention has the advantages of safety, efficiency and low cost, which is applied to the long-term medication for patients with early and intermediate chronic renal failure.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Method of assessing kidney function in a human subject
InactiveUS20110124519A1Improve rendering capabilitiesLibrary screeningDisease diagnosisTherapeutic treatmentNon invasive
Owner:ARGUTUS INTPROP
Method for the early indentification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery
InactiveUS20090238812A1Early detectionConvenient treatmentPeptide/protein ingredientsDisease diagnosisRenal tubuleRecovery stage
A method for the early identification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST, specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB.
Owner:ARGUTUS INTPROP
Reagent sets and gene signatures for renal tubule injury
InactiveUS20060199205A1Improve performanceBioreactor/fermenter combinationsCompound screeningRenal Tubule EpitheliumRenal tubule
Owner:ENTELOS INC
Method for formation of renal tubules
InactiveUS20110236874A1Enhance the imageEasy to transportMicrobiological testing/measurementDead animal preservationCell culture mediaRenal Tubule Epithelium
There is provided a method of making a renal tubule. The method comprises seeding renal tubule cells onto a solid surface; culturing the renal tubule cells in a liquid growth medium to form a monolayer on the solid surface; and continuing culturing the renal tubule cells to form a tubule.
Owner:ZINK DANIELE +3
Method for the early identification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery
InactiveUS20130302819A1Early detectionConvenient treatmentTransferasesDisease diagnosisPatient roomRecovery stage
Owner:KILTY CORMAC GERARD +4
Apparatus for tubulus detection from a tissue biopsy
InactiveUS20190213736A1Advanced technologyEasy to detectImage enhancementImage analysisTissue biopsyMedicine
The present invention relates to an apparatus (10) for tubulus detection from a tissue biopsy. It is described to provide (210) a plurality of 2D images of a tissue biopsy, wherein each 2D image corresponds to a different depth position in the tissue biopsy, and wherein each 2D image comprises image data of the tissue biopsy. A measure of a local variation of intensity is determined (220) in the image data of the tissue biopsy in a region of at least one 2D image. At least part of a tubulus is located (230) in the region of the at least one 2D image on the basis of the determined measure of the local variation of intensity. The locating (230) involves determining (240) locations in the region of the at least one 2D image where the measure of the local variation in intensity is below a threshold. Data representative of the location of the at least part of the tubulus in the region of the at least one 2D image are output (250).
Owner:KONINKLJIJKE PHILIPS NV
Application of astragaloside in preventing and treating type 2 diabetic nephropathy
InactiveCN106309465AReduce excretionLow excretion rateOrganic active ingredientsMetabolism disorderAstragalosideBacteriuria
The invention relates to novel application of astragaloside, in particular to application of astragaloside in preventing and treating type 2 diabetic nephropathy, and provides a study on the protective effect and acting mechanism of astragaloside for type 2 diabetic nephropathy. The results indicate that the astragaloside is capable of reducing urinary albumin excretion rate in type 2 diabetic db / db mouse, improving glomerulus and renal tubule pathological injury, and reducing excretion of urine NAG, NGAL and TGF-Beta1. The astragaloside is also capable of inhibiting activation of Akt / mTOR, NFkB and Erk1 / 2 signal channels, with no significant hepatotoxicity present. In total, the astragaloside can protect type 2 diabetic nephropathy, and its acting mechanism is associated with the inhibition of Akt and its related signal channels.
Owner:SHENZHEN TRADITIONAL CHINESE MEDICINE HOSPITAL
New use of traditional Chinese medicinal material cordyceps cicadae
InactiveCN106138115AGood effectAnthropod material medical ingredientsSkeletal disorderATPaseCreatinine rise
The invention relates to use of cordyceps cicadae in preparation of drugs for preventing or treating gout. According to the use, due to cordyceps cicada preparation products, a novel gout preventing or treating method is provided and is obvious in effect. The cordyceps cicadae have the functions of reducing blood and urine creatinine, increasing endogenous creatinine clearance rate, increasing the content of serum protein, reducing the discharge of urinary protein, and the like. Therefore, the cordyceps cicadae have definite treatment effect on early- and middle-stage chronic renal insufficiency patients. Confirmed by further researches: the cordyceps cicadae have relatively good treatment effect on renal tubulointerstitial lesions and can be used for protecting Na<+>-K<+>-ATPase of renal tubule cells, alleviating cytolysosome and cell lipid peroxidation injury, improving renal hemodynamics and alleviating endothelial cell injury and blood coagulation property.
Owner:湖州新驰医药科技有限公司
Microfluidic proximal tubule kidney-on-chip
ActiveUS20200270582A1Apparatus sterilizationMicrobiological testing/measurementDrug interactionRenal tubule
The present invention relates to microfluidic fluidic devices, methods and systems as microfluidic kidney on-chips, e.g. human Proximal Tubule-Kidney-Chip, Glomerulus (Kidney)-Chip, Collecting Duct (Kidney)-Chip. Devices, methods and systems are described for drug testing including drug transport and renal clearance. Further, such devices, methods and systems are used for determining drug-drug interactions and their effect upon renal transporter functions. Importantly, they may be used for pre-clinical and clinical drug development for treating kidney diseases and for personalized medicine.
Owner:EMULATE INC
Human normal renal tubule primary cell and in-vitro isolated culture and application thereof
ActiveCN110241071AStable traitsVigorous proliferationCell dissociation methodsMicrobiological testing/measurementCell separationRenal tubule
The invention discloses a human normal renal tubule primary cell and in-vitro isolated culture and application thereof. The cell is named human normal renal tubule primary cell XHRN-01, and the preservation number of the cell is CCTCC NO:C201970. An isolated culture method of the primary cell comprises the steps that the clinical postoperative excised tissue near the kidney cancer is acquired in vitro, no cancer cell infection is identified through the pathology, the blood vessels and adipose tissue in the tissue are removed, a tissue sample is subjected to collagenase / trypsin digestion, filtration and low-speed centrifugation to obtain cell pellets, after a red blood cell lysis buffer lyses red blood cells, a COMR complete medium is used for resuspending the cells, and a cell line is constructed through continuous cell culture. The cell can be applied in the physiological study on human normal cells, study on drug toxicity of in-vitro normal cells, study on the pathogenesis of the kidney cancer and related diseases including the renal cancer, chronic nephritis and infectious diseases and study on screening of therapeutic drugs.
Owner:武汉赛尔朗灵科技有限公司
Unilateral ureteral ligation recanalisation animal model and building method thereof
InactiveCN101990859AImprove performanceGood repeatabilityAnimal husbandryUreter implantationElastic plastic
The invention discloses a unilateral ureteral ligation recanalisation animal model and a building method thereof. The method comprises the following steps of: 1) preparing an elastic plastic tube; and 2) after implanting an elastic plastic fat pad into the left ureter of an SD male mouse to pressurize to perform ligation obstruction, performing a surgery 7 days later for the second time, in the surgery, taking out the elastic plastic tube, dredging the left ureter to release the left kidney obstruction and separate the envelope of the left kidney at the same time, and ligaturing the right ureter with a NO. 4 thread. In addition, the invention also discloses the animal model built by the method. The animal model can reduce renal functions and cause renal tubule mesenchyme fibrosis change. The model building period is short; the response is quick; the cost is low; the model is convenient to use; the performance of the model is stable; the repeatability is good; pathomorphological changes of kidney after obstruction can be observed; the functional level of the kidney can be studied; and the relation between the pathomorphological changes and the functional level can be embodied; and the animal model provides a new study target for clinical research and development of medicaments for preventing and treating renal fibrosis.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Hybrid bioartificial kidney
A bioartificial kidney equivalent and a process for producing the bioartificial kidney equivalent. The hybrid bioartificial kidney comprises human proximal and distal renal tubule cells grown on particular synthetic membranes.
Owner:GAMBRO LUNDIA AB
Use of photochemical catalyst nano active water in healing uraemia
InactiveCN101455841ARecovery functionImprove permeabilityEnergy modified materialsAntinoxious agentsArtificial immune systemFiltration membrane
The invention aims to solve the problem of cleaning nephritic lesion to clean the renal glomerulus effectively and thoroughly, and restore the functions of the renal glomerulus, clear renal calculus, and cure uremic patients and 290, 000 sufferers from the melamine tainted milk incident. The technical proposal of the invention comprises: cleaning the nephritic lesion by supplying photo-catalytic nanometer active water to the sufferers by drinking, injecting and targeting; and using the oxygenolysis capacity of free radicals in the photo-catalytic nanometer active water to clean the glomerular filtration membrane and the renal tubule effectively and thoroughly, decompose immune complexes or organic complexes deposited thereon, and diminish inflammation simultaneously so as to restore the functions of the renal glomerulus, establish an artificial immune system, and cure the uremia, nephritis, and the like. Simultaneously, the invention is a pioneering invention, the basic theory for the naissance of free radical physics, free radical chemistry and free radical medicine, and a mark for the naissance of new disciplines, and opens up a new era for the development of the human society. The photo-catalytic nanometer active water can be produced by solar energy, has low cost and is easy to widely popularize and apply.
Owner:张金龙
Method for measuring concentration of cetirizine in human urine
The invention relates to a method for analyzing and measuring the concentration of medicine in excrement, in particular to a method for measuring concentration of cetirizine in human urine, which belongs to the field of medical examination. The method comprises the following steps: after pretreating the sample, applying a high performance liquid chromatograph for detection; the chromatographic column is Waters Nova-Pak C18, the mobile phase is acetonitrile-0.02mol.L-1 sodium dihydrogen phosphate-triethylamine (50:50:0.15), the pH value is 3.07, 0.0105 mol.L-1 of sodium dodecyl sulfate (SDS) is contained, and the flow rate is 1.0mL / min; the column temperature is the room temperature; the internal standard is decloxizine, and the detection wavelength is 229nm. The method has the advantages of high accuracy and preciseness, and simple and rapid operation. The result proves that cetirizine is manly excreted from the kidney, therefore, medicines influencing the secretion of renal tubules possibly affect the excretion of cetirizine from the kidney, and attention is expected to be given to the mutual interaction between medicines when medicines are taken in a combined way.
Owner:曹翠珍
Chinese medicine composition for treating early and medium-term chronic renal failure
InactiveCN101194984BSignificant effectLower medical costsPowder deliveryPill deliveryMetaboliteTurbidity
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Hybrid bioartificial kidney
Owner:GAMBRO LUNDIA AB
N-end fusion protein PC-1-e2 of human multicapsular protein-1
InactiveCN1526736ALow costNo obvious side effectsPeptide/protein ingredientsImmunoglobulins against animals/humansEscherichia coliRenal Tubular Epithelial Cells
The present invention relates to medicine molecular biology engineering technology, and is one kind of 1N-end fusion protein PC-1-e2 of human polycystic protein-1. According to cDNA sequence of human polycystic kidney disease-1 gene and the molecular structure of its encoded product, polycystic protein-1 (PC-1), the gene is cloned to cDNA-PKD1e2 in the N end of the protein and its prokaryotic expression carrier pQE30-PKD1e2 is constituted by means of molecular biology engineering technology. N-end fusion protein PC-1-e2 of PC-1 is induced in colibacillus. Cytobiology experiment shows that the fusion protein has obvious inhibition to the proliferation of the epidermis cell line of in vitro cultured human polycystic kidney cyst lining and the epidermis cell strain of far end renal tubule in dog kidney, so that it may be used in preparing medicine for treating autosomal dominant hereditary polycystic kidney disease, the reagent for the mechanism research of the disease, and anti-PC-1 antibody.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Photocatalysis nano active water for curing uraemia
InactiveCN101658529AHigh reactivityStrong decompositionInorganic active ingredientsUrinary disorderArtificial immune systemKidney stone
The invention aims to solve the problem of cleaning renal focuses and effectively cleans glomeruli of kidney thoroughly to enable the glomeruli of kidney to restore function and remove kidney stone, thereby curing patients with uraemia and 290000 patients suffered from melamine poisonous milk affair. The invention has the technical scheme that photocatalysis nano active water is drunk by a patientor is injected or targeted to the patient to clean the renal focuses, and the oxygenolysis ability of free radicals in the photocatalysis nano active water is utilized to effectively clean glomerularfiltration membrane and renal tubules thoroughly so as to decompose immune compounds or organic compounds depositing on the glomerular filtration membrane and the renal tubules, and at the same time,the water diminishes inflammation to enable the glomeruli of kidney to restore function, and moreover, an artificial immune system is established, thereby curing uraemia, nephritis and the like. Meanwhile, the invention is a pioneering invention, the foundational theory of the naissance of free-radical physics, free-radical chemistry and free-radical medical science, the mark of the naissance ofa new subject and the epoch of initiating progress of the society and the mankind. The photocatalysis nano active water can be produced by solar energy, thereby having low cost and being easy to widely popularize and apply.
Owner:张金龙
Method for detecting content of proximal renal tubule source exosome in urine
InactiveCN110412293AIncrease in sizeAccurate detectionMaterial analysis by observing effect on chemical indicatorColor/spectral properties measurementsBacteriuriaCD63
The invention discloses a method for detecting the content of a proximal renal tubule source exosome in urine. The method includes the following steps of S1, preparing urine exosome suspension; S2, measuring the protein concentration in the urine exosome suspension; S3, separating out the proximal renal tubule source exosome in the urine exosome suspension; S4, detecting the proximal renal tubulesource exosome separated out of urine in the step S3. The high-purity urine exosome is obtained through an ultracentrifugation method, the exosome is then adsorbed by immunomagnetic beads, the problemis solved that the exosome is small in size, and the feasibility of detecting the exosome through a flow cytometry method is increased; the CD63 and CD13 immunolabelling method is adopted for separating out the proximal renal tubule source exosome in the urine and subsequently accurately detecting and analyzing the content of the proximal renal tubule source exosome in the urine.
Owner:THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap